Dual-Functionalized MSCs that Express CX3CR1 and IL-25 Exhibit Enhanced Therapeutic Effects on Inflammatory Bowel Disease
Open Access
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 28 (4) , 1214-1228
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
This publication has 45 references indexed in Scilit:
- Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13Journal of Gastroenterology, 2012
- Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived CellsCirculation, 2012
- Engineered cell homingBlood, 2011
- Genetics and pathogenesis of inflammatory bowel diseaseNature, 2011
- Targeting Improves MSC Treatment of Inflammatory Bowel DiseaseMolecular Therapy, 2010
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced ColitisInflammatory Bowel Diseases, 2009
- Commensal-dependent expression of IL-25 regulates the IL-23–IL-17 axis in the intestineJournal of Experimental Medicine, 2008
- CX3CR1 Is Expressed by Prostate Epithelial Cells and Androgens Regulate the Levels of CX3CL1/Fractalkine in the Bone Marrow: Potential Role in Prostate Cancer Bone TropismCancer Research, 2008
- Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancerGut, 2006